Five recent developments in psoriasis

Research presented at the recent American Academy of Dermatology meeting that Cimzia demonstrates efficacy at 16 weeks as psoriasis treatment was among the recent developments reported on Healio.com/Dermatology.

Other recently reported study findings include Cosentyx showing efficacy in patients with psoriasis after a treatment pause and tapinarof nonsteroidal anti-inflammatory topical cream showing efficacy in treating plaque psoriasis:

Cimzia demonstrates efficacy at 16 weeks as psoriasis treatment

ORLANDO, Fla. — Patients treated with Cimzia reported statistically significant improvement in moderate-to-severe plaque psoriasis at 16 weeks, according to research presented at a late-breaking research forum of the American Academy of Dermatology meeting.

Cimzia (certolizumab pegol, UCB and Dermira) is FDA-approved for treating psoriatic arthritis but not for psoriasis. Read more

Cosentyx shows efficacy in patients with psoriasis after treatment pause

Many patients with moderate-to-severe psoriasis retreated with Consentyx regained previous levels of efficacy after 16 weeks following a relapse during a treatment pause, according to a poster presentation at the American Academy of Dermatology Annual Meeting in Orlando, Florida.

Andrew Blauvelt, MD, MBA, president of the Oregon Medical Research Center, and colleagues presented data for patients retreated with the 300-mg dose of Consentyx (secukinumab, Novartis) following relapse for up to 2 years. Read more

Tapinarof cream shows efficacy in treating plaque psoriasis

Tapinarof nonsteroidal anti-inflammatory topical cream, applied once or twice daily, showed efficacy in treating mild-to-moderate plaque psoriasis, according to late-breaking research presented at the American Academy of Dermatology Annual Meeting in Orlando, Florida.

Tomoko Maeda-Chubachi, MD, presented research on a randomized, evaluator-blinded study of 227 adults with psoriasis; about 80% of patients had mild-to-moderate plaque-type psoriasis. Read more

Mark Lebwohl, MD, reviews efficacy of new biologics for psoriasis

ORLANDO, Fla. — New biologics for psoriasis have achieved high levels of skin clearance in short-term and long-term trials that would have been unexpected a few years ago, according to a presentation at the American Academy of Dermatology Annual Meeting.

Mark Lebwohl, MD, Sol and Clara Kest professor and chairman of the Kimberly and Eric J. Waldman Department of Dermatology at, Icahn School of Medicine at Mount Sinai, gave a presentation on “what’s new in psoriasis” during the Therapeutic Hotline session. Read more

Cosentyx may modify course of psoriasis

Cosentyx may modify the course of moderate-to-severe psoriasis, which could lead to long-term, treatment-free skin clearance, according to data presented at Maui Derm for Dermatologists in Maui, Hawaii.

Cosentyx (secukinumab, Novartis) is the first interleukin-17A (IL-17A) inhibitor to report the potential disease modification, according to a press release from Novartis Read more